MUC18-specific antibody

Anti-MUC18 antibodies with high binding affinity and inhibitory activity provide targeted treatment and diagnosis for malignant melanoma by inhibiting MUC18 expression, addressing the lack of effective cancer treatments.

JP7882548B2Active Publication Date: 2026-06-30MULTITUDE
View PDF 3 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
MULTITUDE
Filing Date
2024-10-17
Publication Date
2026-06-30

AI Technical Summary

Technical Problem

Current treatments for cancer, particularly malignant melanoma, lack effective MUC18 antagonists that can target and inhibit the overexpression of MUC18, a transmembrane protein involved in cell adhesion, which is crucial for tumor penetration and progression.

Method used

Development of anti-MUC18 antibodies with high binding affinity and inhibitory activity, including antibody-drug conjugates and chimeric antigen receptors, designed to target and inhibit MUC18 expression in cancer cells.

Benefits of technology

The anti-MUC18 antibodies effectively inhibit MUC18 activity, reducing cancer cell proliferation and providing diagnostic and therapeutic options for malignant melanoma.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007882548000015
    Figure 0007882548000015
  • Figure 0007882548000016
    Figure 0007882548000016
  • Figure 0007882548000017
    Figure 0007882548000017
Patent Text Reader

Abstract

To provide an antibody specific to MUC18 (also known as MCAM or CD146), and an antibody-drug conjugate (ADC) containing the antibody.SOLUTION: Provided is an anti-MUC18 antibody for treatment and diagnosis, or use of ADC.SELECTED DRAWING: Figure 2
Need to check novelty before this filing date? Find Prior Art